Disclosure: This site earns commissions from affiliate links (Amazon, Etsy, and others) at no extra cost to you.   Full affiliate disclosure →

Updated July 2026 · 8 min read

This article was created with AI assistance.

Beta-Blocker & Calcium-Channel-Blocker Overdose for ICU Nurses 2026 — High-Dose Insulin

⚕️ Medical Disclaimer: This content is for educational purposes only and is intended for licensed healthcare professionals. It does not constitute medical advice and should not replace clinical judgment, facility protocols, or physician orders. Always verify medications, doses, and procedures with your institution's guidelines.

Part of the ICU Emergencies Hub — browse every related guide in one place.

Beta-blocker and calcium-channel-blocker overdoses sit together because they do the same terrible thing from two directions: they drop the heart rate and the blood pressure until the patient is in cardiogenic shock, and they can be stubbornly resistant to the usual pressors. What makes them fascinating — and survivable — is that the most effective treatments are deeply counterintuitive: a massive insulin infusion given with sugar, and high doses of calcium. The nurse who is comfortable running high-dose insulin euglycemic therapy is running one of the true lifesaving ICU protocols.

The short version: Both drug classes cause bradycardia and hypotension heading toward cardiogenic shock. CCBs (especially verapamil/diltiazem) also cause hyperglycemia by blocking insulin release; beta-blockers tend toward normal or low glucose. Beyond fluids and pressors, the standouts are high-dose insulin euglycemic therapy (HIET), IV calcium (best for CCBs), glucagon (classic for beta-blockers), and IV lipid emulsion for refractory collapse. Refractory cases may need pacing or ECMO.

Same shock, two mechanisms

Both classes suppress the heart, but by different levers. Beta-blockers blunt the sympathetic (beta-receptor) drive, slowing the rate and weakening contractility. Calcium-channel blockers block the calcium influx the heart and vessels need — the non-dihydropyridines (verapamil, diltiazem) hit the heart's rate and contractility hard, while the dihydropyridines (amlodipine) act more on the blood vessels and cause profound vasodilation. The end result overlaps: a slow heart, a failing pump, and low vascular tone. One useful bedside discriminator is the glucose: CCBs block pancreatic insulin release and typically produce hyperglycemia, whereas beta-blocker patients usually have normal or low glucose.

FeatureBeta-blockerCalcium-channel blocker
Core mechanismBlocks beta-adrenergic driveBlocks calcium influx into heart/vessels
Heart rate / pumpBradycardia, reduced contractilityBradycardia (verapamil/diltiazem), vasodilation (amlodipine)
Blood glucoseNormal or lowOften high (blocks insulin release)
Mental statusCan be depressed (esp. propranolol, CNS effects)Often preserved until late

High-dose insulin euglycemic therapy: the counterintuitive star

The treatment that surprises people is high-dose insulin euglycemic therapy (HIET): an insulin infusion at doses many times higher than a diabetic drip, run alongside dextrose to keep the blood sugar normal. The poisoned heart shifts to using glucose for fuel, and high-dose insulin acts as an inotrope — improving cardiac contractility — while also helping vascular tone. It works, but it demands disciplined nursing: frequent glucose checks (with dextrose titrated to prevent hypoglycemia) and close potassium monitoring (insulin drives potassium into cells). The effect isn't instant — it takes time to build — so it's started early and not abandoned prematurely.

HIET is a glucose-and-potassium job. The two ways to get hurt running high-dose insulin are unrecognized hypoglycemia and unrecognized hypokalemia. Check point-of-care glucose on a tight schedule, keep dextrose ready and titrating, and monitor potassium closely — but note that mild hypokalemia here reflects intracellular shift, not total-body depletion, so replete thoughtfully rather than aggressively. This is a protocol that lives or dies on the nurse at the bedside.

The rest of the toolkit

Treatment is layered and escalated based on response. IV calcium (calcium chloride or gluconate) helps most in CCB toxicity by overcoming the channel blockade. Glucagon is the classic beta-blocker move, raising heart rate and contractility through a pathway that bypasses the beta receptor (expect vomiting — protect the airway). Standard measures — fluids, atropine for bradycardia (often disappointing), and vasopressors such as norepinephrine or epinephrine — run alongside. IV lipid emulsion is reserved for refractory cardiovascular collapse, especially with lipophilic agents. For overdoses of extended-release products, whole-bowel irrigation may be used to clear un-absorbed pills. When everything fails, transvenous pacing or mechanical support like ECMO can bridge the patient until the drug clears.

Your leverage is running the escalation cleanly. These patients need several therapies at once, titrated to response: get HIET going early and manage its glucose/potassium demands, have calcium and glucagon drawn up, support the pressure with vasopressors, and keep escalating rather than settling for a marginal blood pressure. Anticipate the extended-release "delayed crash," where a patient looks okay for hours and then deteriorates as the pills keep releasing.

The delayed-crash trap

Extended-release formulations are a special hazard. A patient can present awake with only mild bradycardia, then deteriorate hours later as the sustained-release tablets keep dissolving and delivering drug. That means a reassuring early picture with a large reported ingestion of a sustained-release beta-blocker or CCB still warrants ICU-level monitoring, early decontamination when appropriate, and readiness to start therapy the moment the numbers turn. Continuous cardiac monitoring and serial vitals are how you catch the turn before it becomes a code.

The nursing bottom line

Beta-blocker and calcium-channel-blocker overdoses converge on the same lethal picture — bradycardia, hypotension, and cardiogenic shock — from two mechanisms, with hyperglycemia pointing toward a CCB and preserved or low glucose toward a beta-blocker. The standout treatments are counterintuitive: high-dose insulin euglycemic therapy acts as an inotrope and demands vigilant glucose and potassium management, calcium helps most in CCB toxicity, and glucagon is the classic beta-blocker agent, all layered with fluids and vasopressors and, in refractory collapse, lipid emulsion, pacing, or ECMO. Extended-release products can crash a patient hours after a calm presentation. The nurse's highest-value work is running HIET safely and driving the escalation early, because in these poisonings the difference between recovery and arrest is often how aggressively and how soon the team pushes the unconventional therapies.

Related: TCA overdose · Digoxin · Vasopressor guide · Dextrose & hypoglycemia

Educational content for licensed clinicians. Always follow your facility's protocol and provider orders. Not medical advice.

Get The ICU Notebook Newsletter

Clinical tools and career insights for ICU nurses. One email per week, no fluff.

Yes, send it free

No spam. Unsubscribe any time.